Oncotarget

Research Papers:

SHP-1 is a target of regorafenib in colorectal cancer

Li-Ching Fan _, Hao-Wei Teng, Chung-Wai Shiau, Hang Lin, Man-Hsin Hung, Yen-Lin Chen, Jui-Wen Huang, Wei-Tien Tai, Hui-Chuan Yu and Kuen-Feng Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:6243-6251. https://doi.org/10.18632/oncotarget.2191

Metrics: PDF 2242 views  |   HTML 2274 views  |   ?  


Abstract

Li-Ching Fan1,2,*, Hao-Wei Teng3,4,*, Chung-Wai Shiau5,*, Hang Lin1,2, Man-Hsin Hung3,6, Yen-Lin Chen7, Jui-Wen Huang8, Wei-Tien Tai1,2, Hui-Chuan Yu1,2 and Kuen-Feng Chen1,2

1 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

2 National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan

3 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

4 National Yang-Ming University School of Medicine, Taipei, Taiwan

5 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan

6 Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan

7 Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan

8 Industrial Technology Research Institute, Hsin-Chu, Taiwan

* These authors contributed equally to this work

Correspondence:

Kuen-Feng Chen, email:

Keywords: SHP-1, Regorafenib, Colorectal cancer, STAT3, Apoptosis

Received: April 10, 2014 Accepted: July 8, 2014 Published: July 9, 2014

Abstract

Regorafenib is an inhibitor of multiple protein kinases which exerts antitumor and antimetastatic activities in metastatic colorectal cancer (CRC). SH2 domain-containing phosphatase 1 (SHP-1) is reported to have tumor suppressive potential because it acts as a negative regulator of p-STAT3Tyr705 signaling. However, little is known about the mechanism regarding regorafenib affects SHP-1 tyrosine phosphatase activity and leads to apoptosis and tumor suppression in CRC. Here, we found that regorafenib triggered apoptotic cell death and significantly enhanced SHP-1 activity, which dramatically decreased the phosphorylated form of STAT3 at Tyr705 (p-STAT3Tyr705). Importantly, regorafenib augmented SHP-1 activity by direct disruption of the association between N-SH2 and catalytic PTP domain of SHP-1. Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 blocked the effect of regorafenib-induced SHP-1 activity, growth inhibition and a decrease of p-STAT3Tyr705 expression, suggesting that regorafenib triggers a conformational change in SHP-1 by relieving its autoinhibition. In vivo assay showed that regorafenib significantly inhibited xenograft growth and decreased p-STAT3Tyr705 expression but induced higher SHP-1 activity. Collectively, regorafenib is a novel SHP-1 agonist exerts superior anti-tumor effects by enhancing SHP-1 activity that directly targets p-STAT3Tyr705. Small molecule-enhancement of SHP-1 activity may be a promising therapeutic approach for CRC treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2191